Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin in BDD and OCD
NCT02671266Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2014
- Primary completion
- Oct 2017
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in body dysmorphic disorder (BDD) and obsessive compulsive disorder (OCD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Emotion Recognition Questionnaire. Started Dec 2014; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
body dysmorphic disorder (BDD)obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT02671266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02671266.